Scorpius Holdings Achieves 359% Year-Over-Year Increase in Revenue for the First Quarter of 2024
Rhea-AI Summary
Scorpius Holdings (NYSE American: SCPX) reported a 359% year-over-year increase in revenue for Q1 2024, reaching $3.5 million, compared to $0.8 million in Q1 2023.
The jump is attributed to expanded biomanufacturing operations and service offerings. Operating expenses were reduced by 34%, and net loss decreased by 64%, from $12.8 million to $4.4 million.
Key reductions included a $2.4 million drop in R&D expenses and a $1.5 million decrease in SG&A expenses. The company noted a growing revenue backlog of $10.8 million as of March 31, 2024.
Scorpius also raised $6.0 million through a public offering in May 2024, and held $1.7 million in cash and short-term investments at the end of Q1 2024.
Positive
- 359% increase in Q1 2024 revenue year-over-year, reaching $3.5 million.
- Operating expenses reduced by 34% compared to the same period last year.
- Net loss decreased by 64%, from $12.8 million to $4.4 million.
- Research and development expenses dropped by $2.4 million.
- Selling, general, and administrative expenses reduced by $1.5 million.
- Revenue backlog of $10.8 million as of March 31, 2024.
- Raised $6.0 million through a public offering in May 2024.
Negative
- Net loss still significant at $4.4 million for Q1 2024.
- Operating cash at a low $1.7 million as of March 31, 2024.
- Increased cost of revenues to $0.9 million due to expanded services.
News Market Reaction – SCPX
In the trading session that priced this news, SCPX gained 7.60%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Reduces operating expenses by
DURHAM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided strategic, financial, and operational updates for the first quarter ended March 31, 2024.
Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, “We are successfully executing our strategy to enhance revenue and reduce costs as we seek to become cash flow positive in the near future. This quarter is indicative of this goal as we achieved a
2023 Financial Results
For the three months ended March 31, 2024, the Company recognized
Cost of revenues were
Research and development expenses were
Selling, general and administrative expenses were
For the three months ended March 31, 2024, the change in fair value of contingent earn-out receivable, related party, was
Total non-operating income was
Net loss attributable to Scorpius was approximately
As of March 31, 2024, the Company had approximately
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as becoming cash flow positive in the near future, the performance reinforcing the growing demand for the Company’s services and its prudent financial management; the business model being poised to generate meaningful cash flow; continuing to grow sales and increase utilization of the state-of-the-art San Antonio campus which will allow the Company to achieve meaningful operating leverage, and the future for Scorpius being brighter than ever. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to expand its large molecule biomanufacturing CDMO services, attract new customers, profit from its bookings and continue to grow revenue; the ability to capture a meaningful market share; the ability to generate meaningful cash flow and become cash flow positive; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
ir@scorpiusbiologics.com
